As an established target for tumor immunotherapy, PD-L1 has garnered extensive research attention across various domains, including the development of monoclonal antibodies, small molecule inhibitors aimed at protein–protein interaction modulation, and strategies to alter the characteristics of cold and hot tumors. The gene discussed is CD274; the disease is neoplasm.